A peripheral blood phosphatidylethanolamine biomarker for objective diagnosis of depression

By detecting changes in the levels of phosphatidylethanolamine (18:1/18:3) in peripheral blood, the objectivity problem in the diagnosis of depression has been solved, achieving a diagnostic effect with high sensitivity and high specificity, and providing a new auxiliary diagnostic method.

CN122306988APending Publication Date: 2026-06-30BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV
Filing Date
2026-04-03
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Current diagnostic methods for depression lack objectivity, have low accuracy, high rates of misdiagnosis and missed diagnosis, and have unclear pathogenesis, lacking effective biomarkers for auxiliary diagnosis.

Method used

Using changes in the concentration of phosphatidylethanolamine (18:1/18:3) in peripheral blood as a biomarker, and detecting it using liquid chromatography-mass spectrometry, this study provides an auxiliary diagnostic method for depression. The diagnostic criteria are defined as a peripheral blood phosphatidylethanolamine (18:1/18:3) concentration below 43.0 nmol to indicate suspected depression.

Benefits of technology

It achieves objective diagnosis of depression with high sensitivity, high specificity and high accuracy, reduces detection costs and technical complexity, provides new technical means for early screening and auxiliary diagnosis, and has good prospects for clinical translation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.
Need to check novelty before this filing date? Find Prior Art